CytoTools is led by a highly experienced management team with a strong track record in research and development, the pharmaceutical industry and finance. It is actively supported by an industry-leading board of directors and a top-class scientific advisory board.
Dr. Mark-Andre Freyberg – Chief Executive Officer
Dr. Mark-Andre Freyberg is responsible for CytoTools AG’s financing and the commercialization of the Company’s drugs. As co-founder and managing director of CytoTools AG, he coordinated the research activities and was responsible for the first successful rounds of financing. Dr. Freyberg has won numerous grants from the Federal Ministry of Education and Research (BMBF) for CytoTools and reached the proof of concept of the previous basic research in three animal models. In 2004, he was instrumental in establishing the DermaTools Biotech GmbH, as well as founding CytoPharma GmbH in 2006. Previously he was a Project Manager of Cell Culture Technology at the Institute of Biochemistry at the Technical University of Darmstadt, Germany.
Dr. Freyberg has a PhD in biochemistry and biotechnology from the Technical University of Darmstadt, Germany and holds a diploma in biology with focus on microbiology.
Dr. Dirk Kaiser – Chief Research Officer
Dr. Dirk Kaiser coordinates the extensive research and development work within CytoTools’ subsidiaries and is responsible for the organization and control during the conduct of the clinical trials. As a co-founder, Dr. Kaiser has been a part of the management team since 2000. Dr. Kaiser is also responsible for the scientific development of the therapeutic assets and the consistent maintenance and extension of the patent portfolio.
In 2000, Dr. Kaiser obtained a PhD in chemistry from the Institute of Biochemistry at the Technical University of Darmstadt, Germany and has a diploma in chemistry from the Technical University of Darmstadt.
Dr. Wilfried Hauke - Chief Medical Officer
Dr Wilfried Hauke MD coordinates all topics related to the medical area including clinical development, regulatory affairs, and pharmacovigilance.
Dr. Hauke has over 30 years’ experience in the international pharmaceutical industry and was responsible in different positions (amongst others for Hoechst AG, Roussel UCLAF, Trophos) for the clinical development of new chemical entities taking into account relevant regulatory aspects. As Qualified Person for Pharmacovigilance (QPPV) he is familiar with all aspects of drug saftey.
He studied human medicine at Ludwig-Maximilians-University in München, where he received the licence to practice medicine. His PhD was awarded by the Johann Wolfgang Goethe-University in Frankfurt.